Author | Lightnews

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Apr 24

How fortunate are we to have @kimrynrathmell.bsky.social
bring her wealth of experience & outstanding leadership to @osucccjames.bsky.social
@osuwexmed.bsky.social ! Welcome to #BuckeyeNation Dr. Rathmell! @osuhematology.bsky.social

3

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Apr 10

The closest I’m ever going to come to a National Football Championship Trophy ! 🙏🏽 @Peletonia @Huntington_Bank @OhioStateFB Proud to be a Peletonia funded @osuhematology.bsky.social @osucccjames.bsky.social Researcher & part of #BuckeyeNation

3

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Apr 9

What other kinds of presentations are there (other than fabulous ? ) Clearly, I have been attending the wrong conferences so far without fabulous presentations 😂

1

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Anand Patel @anand-88-patel.bsky.social · Apr 6

a nice analysis from the BEAT AML study outlining molecular characteristics of adults >60 with AML

www.nature.com/articles/s41...

2 4

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Barnes & Noble @barnesandnoble.com · Apr 6

Hi.

Books are incredibly important.

Please let them be.

220 3K 20K

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Anand Patel @anand-88-patel.bsky.social · Apr 2

helpful sub-group analysis of Aza + Ven studies looking at treatment-naive t-AML and AML arising from MDS or CMML!

www.nature.com/articles/s41...

1 4

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Apr 2

Very proud to have played a role in this study with my study chair Dr. Eric Huselton from University of Rochester - please consider your patients for this study @osuhematology.bsky.social @osucccjames.bsky.social @swog.org @ash.hematology.org

SWOG Cancer Research Network @swog.org · Apr 2

#myeloMATCH sub-study MM1OA-S03 is open!
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social

myeloMATCH Precision Medicine in Myeloid Cancer

3 2

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Mark Cuban @mcuban.bsky.social · Mar 28

If you know anyone that takes Sprycell, please let them know !!!

Mark Cuban Cost Plus Drug Company @costplusdrugs.com · Mar 28

🚨 𝐌𝐀𝐒𝐒𝐈𝐕𝐄 𝐏𝐑𝐈𝐂𝐄 𝐃𝐑𝐎𝐏! 📢

We just dropped the price of all Dasatinib strengths by over 90% on costplusdrugs.com!

Why? Because our pricing model is simple:
When we get a lower price, you get a lower price.

🔗 www.costplusdrugs.com/medications/...

300 2K 7.6K

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Anand Patel @anand-88-patel.bsky.social · Mar 28

A great @bloodjournal.bsky.social paper by @beatalleukemia.bsky.social et al on clinical trial eligibility for patients with MDS!

ashpublications.org/blood/articl...

1 3

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Mar 28

Thrilled to see our effort on behalf of @ic_MDS group out in @BloodJournal about reducing clinical trial eligibility barriers for our MDS patients. Commentary by Lionel Ades on ‘ releasing the brake’ on eligibility criteria. @Dr_AmerZeidan #mdssm ashpublications.org/blood/article/…

1 1

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Bruce Levine, Ph.D. 🇺🇦 @bllphd.bsky.social · Mar 28

Happy CD3 CD28 T Cell Stimulation Day to all who celebrate

2 7

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Mar 26

Calling all hematologists - how are you interpreting the results of the TRAIN trial vs the SAHARA trial in patients with blood cancers & acute cerebral bleeding events ?
jamanetwork.com/journals/jam...
www.nejm.org/doi/full/10....
@shematologist.medsky.social @bloodman.bsky.social

1

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Mar 25

Sunset & snow makes for good hunting.#springbreak

1

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Mar 20

I would be the second to last one 😂

PedsHemeDoc @pedshemedoc.bsky.social · Mar 20

Which neutrophil are you? Tag yourself!

1

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Anand Patel @anand-88-patel.bsky.social · Mar 18

a very nice review in AJH on considerations of MPN management in women!

onlinelibrary.wiley.com/doi/full/10....

1 2

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Mar 19

👇🏾

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

American Society of Hematology @ash.hematology.org · Mar 19

Could adjusting a simple blood test reference range save patients unnecessary stress?

Recent research highlights Duffy null-associated neutrophil count (DANC) and the risk it imposes on certain ancestral backgrounds.

Enroll in the ASH course: bit.ly/duffynull

#HemeSky #Hematology #MedSky

Researchers at Brigham and Women's Hospital, Boston, recently found that ANC in 120 people with the Duffy null blood group can range from 1210-5390 microliters: significantly lower than most institutional reference ranges

Historically, ANC reference ranges have had a lower limit of 2000 microliters, but these were based on studies in populations with European ancestry, in whom the Duffy null phenotype is rare.

2/3 of people in the USA who self-identify as African-American have the Duffy null phenotype. It is also more common in people of Middle East and North African ancestry.

2 7 22

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

Ohio State Hematology @osuhematology.bsky.social · Mar 12

The 2025 @castleconnolly.bsky.social Exceptional Women in Medicine is out!🎉This honor celebrates🔝female physicians for their leadership & expertise.
👏 Congrats to the OSUCCCJames Heme honorees:
Jennifer Woyach
Uma Borate @beatalleukemia.bsky.social
Alice Mims
Ashley Rosko
Kami Maddocks
Kerry Rogers

1 1

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Dec 9

Love @leegrimeslab.bsky.social for representing!!

1

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Dec 6

EST to PST problems. Awake 3 hrs before #ASH24 activities start but very excited for our Scientific Workshop on DCTs & AI from 2-5 pm today! If you are a trial sponsor , investigator , statistician or involved in any clinical research- this one is ‘A must attend’ ! #DCTs

2

Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital

American Society of Hematology @ash.hematology.org · Dec 5

Great haiku! The excitement for #ASH24 will power us through this early morning!

1 2

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Dec 5

I posted the exact same thing except in an ASHaiku 😂

2

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Dec 5

Waking up before the crack of dawn
EST to PST
Excited for #ASH24
#ASHaiku

1 9

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Dec 4

Our DCT and AI Scientific Workshop on Friday! Come see us !!

4

Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · Nov 26

Our Friday Scientific Workshop on Real World DCTs in Hematology &AI has a fantastic line up of speakers : clinical trialists ( IIT PIs included) statisticians, pharma sponsors, & regulatory experts discussing all things practical about hematology DCTs - join us ! 👇🏾#ASH24

2 4